Clari Vest Asset Management LLC Cyma Bay Therapeutics, Inc. Transaction History

Clari Vest Asset Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$12.63 - $24.47 $303 - $587	24 Added 0.02%	96,505 $2.28 Million
Q3 2023 Nov 13, 2023	SELL	$10.86 - $17.62 $690,696 - $1.12 Million	-63,600 Reduced 39.73%	96,481 $1.44 Million
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $216,181 - $316,893	28,940 Added 22.07%	160,081 $1.75 Million
Q1 2023 May 08, 2023	SELL	$5.88 - $9.59 $934 - $1,524	-159 Reduced 0.12%	131,141 $1.14 Million
Q4 2022 Feb 14, 2023	SELL	$3.22 - $6.27 $5,474 - $10,659	-1,700 Reduced 1.28%	131,300 $823,000
Q1 2022 May 04, 2022	SELL	$2.77 - $3.64 $54,015 - $70,980	-19,500 Reduced 12.79%	133,000 $413,000
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $125,970 - $179,400	39,000 Added 34.36%	152,500 $515,000
Q3 2021 Nov 08, 2021	SELL	$3.47 - $4.42 $2,429 - $3,094	-700 Reduced 0.61%	113,500 $415,000
Q1 2021 May 13, 2021	BUY	$4.23 - $6.55 $104,481 - $161,785	24,700 Added 27.6%	114,200 $518,000
Q4 2020 Feb 09, 2021	SELL	$5.73 - $9.03 $93,399 - $147,189	-16,300 Reduced 15.41%	89,500 $514,000
Q3 2020 Nov 09, 2020	SELL	$3.32 - $7.24 $21,912 - $47,784	-6,600 Reduced 5.87%	105,800 $766,000
Q2 2020 Aug 12, 2020	BUY	$1.41 - $4.25 $158,484 - $477,700	112,400 New	112,400 $392,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Clari Vest Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Clari Vest Asset Management LLC with notifications on news.